Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review

被引：0
|
作者：
Mercedes Kile
Patcharaporn Sudchada
机构：
[1] University of Wisconsin-Madison,School of Pharmacy
[2] Naresuan University,Faculty of Pharmaceutical Sciences
来源：
International Urology and Nephrology | 2021年 / 53卷
关键词：
Chronic kidney disease; Anemia; Iron; ESA; Hypoxia-inducible factor prolyl hydroxylase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 290
页数：7
相关论文
共 50 条
  • [1] Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review
    Kile, Mercedes
    Sudchada, Patcharaporn
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (02) : 283 - 290
  • [2] Hypoxia-inducible factor?prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
    Haase, Volker H.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 8 - 25
  • [3] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease
    Bartnicki, Piotr
    [J]. BIOMEDICINES, 2024, 12 (08)
  • [4] Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza, Ernane
    Cho, Katherine H.
    Harris, Shelby T.
    Flindt, Naomi R.
    Watt, Richard K.
    Pai, Amy Barton
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 831 - 844
  • [5] Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
    Kurata, Yu
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 414 - 422
  • [6] Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Sugahara, Mai
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. PHARMACOLOGY & THERAPEUTICS, 2022, 239
  • [7] Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease
    Sakashita, Midori
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. CKD-ASSOCIATED COMPLICATIONS: PROGRESS IN THE LAST HALF CENTURY, 2019, 198 : 112 - 123
  • [8] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Post Kidney Transplant Anemia
    Ogata, Masatomo
    Miyauchi, Takamasa
    Murata, Marie
    Terashita, Maho
    Osako, Kiyomi
    Shinoda, Kazunobu
    Shibagaki, Yugo
    Yazawa, Masahiko
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 552 - 552
  • [9] Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages
    Mima, Akira
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 912
  • [10] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in CKD
    Parfrey, Patrick
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (25): : 2390 - 2391
12345